Our precision molecules hit tumors at their Achilles heel.
Taming the Forces that Drive Cancer
Genetic Alterations Expose Tumor Vulnerabilities
Molecular Machines Drive Tumor Evolution
A majority of cancers can be targeted by disrupting the machines that are vital to the dynamic reorganization of the tumor genome.
Hitting the Achilles Heel of our Targets
Eisbach’s discovery engine exploits the unique key that ignites the activity of each of our targets, generating new classes of allosteric drugs.
A Bold Vision for Precision Medicine
By pioneering drugs which selectively tame the machines that disrupt genome reorganization, we stop tumor growth and enable new cancer therapies.
Our Science
We develop smart drugs targeting the machines that remodel the genome
Tumor genomes reveal that molecular machines which reorganize chromatin and genome structure have critical and typically very specific roles in the development of a majority of human cancers.
We target two classes of molecular machines vital for genome reorganisation
Eisbach develops selective drugs targeting nucleosome remodeling enzymes and DNA-dependent nuclear helicases. Chromatin remodellers turn genes on/off or promote DNA repair by changing the way that the tumor DNA is packaged within the cancer cell. Other nuclear helicases are absolutely critical for many DNA repair pathways critical to tumor cell evolution and survival.
DNA damage activates PARPs, which unleashes a machine that is key to genome reorganization
DNA damage in cancer cells leads to the activation of PARP1 and PARP2 enzymes. This generates an allosteric signal that is key to the recruitment of the nucleosome remodeling enzyme ALC1. Upon recognizing this signal, the ALC1 machine powers the repair of damaged DNA by reorganizing chromatin structure and modulating the DNA retention of PARPs and other DNA repair enzymes. DNA damage is thus efficiently repaired when ALC1 is active. Disrupting ALC1 activity in cancer cells suppresses DNA damage repair pathways vital to cancer cells and robustly potentiates the efficacy of chemotherapies and PARP inhibitors.
Our Approach
We are a pioneering precision oncology company focused on genome reorganization
Eisbach enables the potential of synthetic lethality by exploiting the unique molecular vulnerabilities present in validated cancer targets. Our ALLOS platform systematically recapitulates the tight controls that strictly regulate the activity of our cancer-driving molecular machines. We exploit this regulation to develop targeted allosteric therapies for chromatin reorganization.
Our privately-held company was founded in 2019 by academic and drug discovery pioneers in order to enable the full potential of synthetic lethality.
We strive for game-changing and safe synthetic-lethal therapies
Now is the time to leverage the power of tumor genomics to develop the right drugs for the right patients. We now know that tumors harbor genetic fingerprints that reveal specific, targetable vulnerabilities. This concept, known as synthetic lethality, allows us to target specific proteins that are essential for the survival of cancer cells, but not normal cells. By targeting these Achilles heels, the cancer cells are unable to repair their genome and die, while non-tumor cells are spared.
A leading example of synthetic lethality in cancer therapy involves PARP inhibitors, which impact related DNA repair pathways to those we target. While powerful and effective, this approach can be challenged by dose-limiting toxicities and the development of resistance to PARP inhibitors.
Enabling synthetic-lethality by targeting molecular vulnerabilities
Eisbach combines synthetic lethality with a disruptive, orthogonal approach to drug discovery, our proprietary ALLOS platform. We focus on the molecular machines essential to the dynamic reorganization of the cancer genome. Next, we discover the unique key that is required to ignite the power of each of our machines. This allows us to systematically develop allosteric drugs that disrupt these vital molecular controls.
Our groundbreaking discovery engine ALLOS crafts drugs that are effective, selective and show fewer side effects compared to traditional approaches. We turn the promise of synthetic lethality into reality by developing first-in-class therapies, by enabling powerful combination treatments and by suppressing resistance mechanisms toward targeted cancer therapies.
Our Pipeline
Our small molecule candidates inhibit the activation of cancer-promoting molecular machines.
Eisbach’s pipeline of allosteric drugs targeting chromatin reorganization has the potential to enable the fourth wave of therapeutics in oncology.
Target 1: ALC1
Enabling novel synthetic-lethal relationships in HRD tumors that suppress PARPi resistance
Target selection
ALC1 (amplified in liver cancer 1; also known as CHD1L, chromodomain helicase DNA-binding protein 1-like) is a chromatin remodeling enzyme that modulates DNA damage and repair. Its expression is increased in breast and ovarian cancers marked by deficiencies in homologous recombination (HRD-positive). Its absence robustly potentiates the efficacy of PARP inhibitors and a wide range of standard-of-care chemotherapies. ALC1 inhibitors are expected to induce synthetic lethality in HR-deficient tumors, to potentiate PARP inhibitors in patients who develop PARPi resistance and to enable potent combination therapies. Available diagnostic approaches enable the selection of patients in the clinic.
Selectivity by design
Selective inhibitors for ALC1 have to potential to exhibit a wide therapeutic window, since the ALC1 gene is not essential for life, but rather plays a targeted role in situations of high DNA damage, as can be present in cancer or when a patient’s tumor is treated with DNA damage agents or radiation therapy. The critical dependence of ALC1 activity on its unique allosteric key (known as poly-ADP-ribose) allowed us to screen for and develop selective drugs with a superior safety and tolerability profile compared to existing therapies.
Target 2: CHD1
Allosteric inhibition for beneficial immunomodulation in synthetic-lethal PTEN-deficient cancer
Target selection
CHD1 (chromodomain helicase DNA-binding protein 1) is a chromatin remodeller that regulates gene expression, plays a role in DNA repair and modulates the immune system to impact the tumor microenvironment. Its absence disables the ability of cancer cells deficient in the PTEN tumor suppressor to grow. Genetic deletion of CHD1 reduces metastases in animals models of prostate cancer. CHD1 inhibitors are expected to induce synthetic lethality in PTEN-deficient tumors, enabling novel immunomodulatory approaches in oncology.
Nuclear helicases
Allosteric targeting of validated, synthetic lethal molecular machines
Target selection
A wide range of additional, DNA-dependent nuclear enzymes and molecular machines contain helicase engines that are essential in highly specific, genetic tumor contexts, while being dispensable in non-cancer cells. These synthetic lethal vulnerabilities represent a promising avenue toward the development of novel, targeted therapies in defined cancer populations.
Our Team
Celia Schell
Clinical Operations
William Menzer
Medicinal Chemistry & CMC
Markus Lechner
Preclinical
Dana Matzek
Animal Models
Xin Zhang
Cancer Biology
Lucas Kalczynski
Preclinical
Nina Nguyen
Clinical Study Coordinator
Peter Sennhenn
Medicinal Chemistry
Jonathan Iorio
Director of Finance
Deepak
Biochemistry
Andreas Ladurner
Science
Adrian Schomburg
Operations
Gunnar Knobloch
Biochemistry
Jörk Zwicker
IP
Margit Schmidt
Clinical Operations
Daniel Gau
Business Development
Junmei Liu
Cancer Biology
Join us
We are a bold, curious and relentless team.
We will transform the lives of cancer patients by delivering on the promise of synthetic lethality through allosteric drugs.
If you are a driven, committed, and inventive professional looking to make a significant impact for our patients, we love to hear from you.
We deliver on the promise of our cutting-edge science to pioneer new drugs. Together, we pledge to transform the lives of patients and be stewards of our community.
How will you apply your curiosity? Tell us at: careers@eisbach.bio
Join Eisbach Bio GmbH as PhD Fellow!
Application Deadline: June 20th, 2025
EISBACH BIO GmbH is a biotechnology company based in Planegg, near Munich, Germany. It specializes in drug discovery and development, particularly targeting chromatin remodeling enzymes and synthetic lethality pathways for cancer therapy. The company leverages its molecular expertise in epigenetics and genome stability to develop innovative small-molecule inhibitors that target specific vulnerabilities in cancer cells. Its platform addresses the inhibiton of target enzymes using allosteric approaches that hit the unique activation mechanisms that underlie the regulation of the molecular machines that the company focuses on. In doing so, EISBACH’s speerheads the development of first-in-class, next-generation precision oncology treatments. EISBACH BIO collaborates with research institutions and pharmaceutical companies to advance its pipeline of drug candidates, the first of which has entered clinical Phase I/II testing at the MD Anderson Cancer Center in Houston, TX (USA).
Eisbach Bio GmbH focuses on pioneering precision oncology through the development of allosteric drugs that target molecular machines essential for tumor genome reorganization. Utilizing our proprietary ALLOS platform, we identify and exploit the genetic vulnerabilities of cancer cells by targeting the unique molecular vulnerabilities of our target enzymes, notably the allosteric sites that we identify, validate and target using small molecule drug candidates. Eisbach’s research encompasses nucleosome remodeling enzymes, DNA-dependent nuclear helicases as well as nuclear PARP family enzymes, all of which are critical for efficient DNA repair and chromatin reorganization. Our allosteric approach aims to create safe, orally bioavailable first-in-class or best-in-class anti-tumor therapies that induce synthetic lethality in cancer cells, halting tumor growth while minimizing damage to healthy cells, thus significantly reducing side-effects. Our lead candidate includes a small molecule inhibitor of ALC1, an important molecular machine that reorganizes the genome upon DNA damage, which has entered clinical Phase I/II trials in the autumn 2024.
In the context of the European Horizon funded Marie Skłodowska-Curie Actions – doctoral network HubMOL – Hub Molecules of Metabolism and Signalling – Key regulators of Life we have 1 PhD position available at Eisbach Bio GmbH. HubMOL brings together internationally leading academic and industrial expertise in epigenetics, mathematical modelling and high-resolution stable isotope labelling based analysis of the dynamics of metabolic cofactors and post translational modifications (PTMs) and will use advanced in vitro and animal models for translational studies to develop knowledge based nutritional intervention strategies for hub molecules. The hub molecules of life that include ATP (adenosine triphosphate), NAD (nicotinamide adenine dinucleotide), CoA (coenzyme A), FAD (flavine adenine dinucleotide) and SAM (S-adenosylmethionine), comprise a set of cofactors that are crucial for all cellular functions. More information can be found at the project website: www.hubmol.eu
Research topic:
Synergy between HPF1-mediated serine ADP-ribosylation of chromatin and ALC1 chromatin remodeller function in the DNA damage mediated and NAD-dependent activation of the nuclear enzymes PARP1/2.
Background: The conversion of the metabolite NAD into poly-(ADP-ribose) (PAR) during DNA damage is crucial in cancer. PARP1/2 inhibitors are clinically useful but have toxicity and resistance issues. HPF1 completely alters PARylation’s target amino acid in the DNA damage response, yet its potential as a cancer target remains underexplored. Objectives: (1) Dissect the functions and biological roles of ALC1 and HPF1 in PARP1/2-mediated DNA damage responses; (2) Determine the role of HPF1 in the NAD-dependent and poly-(ADP-ribose)-mediated recruitment of ALC1 chromatin remodeller to DNA damage sites; (3) Establish the mechanism of PARP inhibitor sensitization mediated by ALC1 and HPF1 in isolation and together.
Supervisor: Andreas Ladurner : andreas@eisbach.bio Link to DC7: HubMOL | UiT
Gross salary: Annual gross salary: 38.000 EUR, Family allowance yearly: +7.200 EUR if applicable
Requirements:
Research Field: Biological sciences
Education Level: Master’s degree or equivalent
Skills/Qualifications:
- A master in biochemistry, cell biology, biomedicine with good understanding of biochemistry
- Proven prior knowledge in hub molecule relevant topics
- A high level of motivation and interest for topics of HubMOL
- High-level of collaborative and communicative skills
- Relevant expertise in cell metabolism and fields related to the HubMOL projects
- Excellent level of English speaking and writing skills (required).
Specific Requirements:
We are seeking a highly motivated candidate with:
- Academic Background:
- A Master’s degree (or equivalent) in Molecular Biology, Cell Biology, Cancer Biology, Biochemistry, Biophysics, or related fields.
- Research Experience:
- Experience in chromatin biology, DNA damage repair, or epigenetics.
- Experience with techniques such as protein expression/purification, CRISPR/Cas9 gene editing, and advanced microscopy is highly desirable.
- Technical Skills:
- Proficiency in molecular cloning, cell culture, and biochemical assays.
- Familiarity with omics-based approaches (e.g., proteomics, transcriptomics) is a plus.
- Soft Skills:
- Strong analytical and problem-solving abilities.
- Aptitude for teamwork
- Effective written and oral communication skills in English.
- Language Skills:
- Fluency in English is required
- Motivation: A passion for precision oncology and a drive to explore the therapeutic potential of novel drug targets will be critical for success in this role.
Additional Information
Mobility rule:
Researchers can be of any nationality, but they are required to undertake physical, transnational mobility (i.e., move from one country to another) when taking up their appointment.
Additionally, researchers shall not have resided or carried out their main activity in Germany for more than 12 months in the 3 years immediately prior to the reference date.
Researchers who are refugees in an EU Member State or a Horizon Europe Associated Country according to the Geneva Convention are exempted from the mobility rules above if they fulfill the other eligibility conditions.
Doctoral Candidates (DCs) rule:
Applicants must be doctoral candidates, i.e. not already in possession of a doctoral degree at the date of the recruitment. Researchers who have successfully defended their doctoral thesis but who have not yet formally been awarded the doctoral degree will not be considered eligible. See Article 6.2.A (b) (i) of the HE unit model grant agreement.
Applicants must meet the admission requirements of the doctorate degree program of the hiring institutions for each position.
Selection process
The applicants will be assessed by an expert committee. The committee’s mandate is to undertake an assessment of the applicants’ qualifications based on the written material presented by the applicants, and the detailed description draw up for the positions.
The applicants who are assessed as best qualified will be called to an interview. There will be a two-stage interview process. The interview should among other things, aim to clarify the applicant’s motivation and personal suitability for the position.
How to Apply:
If you’re a driven, committed student ready to transform the lives of patients and make a meaningful impact, we’d love to hear from you. Send us your CV and a cover letter detailing your experience and suitability to careers@eisbach.bio.
Let’s work together to pioneer groundbreaking therapies and deliver on the promise of our science.
About us
Eisbach is a cutting-edge clinical-stage biotech based in Munich, Germany, with clinical operations in Houston, Texas, focused on the discovery and development of transformative cancer drugs. Leveraging our unique insights into the allosteric activation of targeted molecular machines, we create effective and safe solutions in areas of unmet need.
Position Overview
We seek a deeply-committed, driven and experienced clinical oncologist, who will drive of our clinical oncology programs as Chief Medical Officer (CMO). You will refine and guide our clinical strategy and execute all phases of clinical development. Your leadership, strategic vision, expertise, hands-on resourcefulness and great adaptability will be vital in enabling the transformative potential of our allosteric pipeline into ground-breaking, first-in-class therapies. You will further develop our clinical team and lead our driven startup with us.
About you
Leadership skills: Demonstrated ability to lead cross-functional teams, handle complex projects, get involved where needed and manage costs. Proven track-record of driving clinical programs to regulatory approval.
Academic & Professional background: An advanced degree (MD, PhD, or PharmD) in a relevant discipline is preferred. Proven track record in Phase I – III clinical studies and trial design, including regulatory submissions in oncology.
Strategic thinking: You possess the ability to shape and articulate a clear strategic clinical vision. Highly capable of making decisions based on thorough risk-assessment and forward-planning.
Industry experience: Minimum of 5 years in the pharmaceutical or biotech industry developing new therapeutic modalities. Robust expertise with regulatory authorities, ethics committees and KOLs.
Communication skills: Exceptional ability to communicate complex topics clearly and effectively, in writing and verbally. Fluent in English, with proficiency in other languages and global experience a plus.
Team dynamics: A collaborative leader who can effectively interface with internal teams, external partners, and all stakeholders. You build on our international team by cultivating a culture of excellence, inclusion, and diversity within the work environment and beyond.
Adaptability: Comfortable navigating the evolving landscape of drug development and regulatory requirements. Able to recognize and act on clinicals needs and commercial opportunities, respond to challenges, adapt to evolving priorities, and excel in a fast-paced team.
We offer a competitive salary, comprehensive benefits and a Stock Option Plan that allows you to share in the long-term success and growth of our company Eisbach.
If you are a driven, committed, and inventive professional looking to make a significant impact for our patients, we love to hear from you.
To apply, please submit your CV and an informative coverletter detailing your experience and suitability.
We deliver on the promise of our cutting-edge science to pioneer new drugs. Together, we pledge to transform the lives of patients and be stewards of our community.
How will you apply your curiosity? Tell us at: careers@eisbach.bio
News
Martinsried, Germany – November 26, 2024 – Eisbach Bio GmbH, a pioneering precision oncology company, is pleased to announce the receipt of a Texas Therapeutics Company Award from the Cancer Prevention and Research Institute of Texas (CPRIT). This prestigious grant of US$4.75 million will support the clinical development of Eisbach’s first-in-class allosteric small molecule inhibitor EIS-12656 targeting ALC1, a chromatin remodeling enzyme and helicase that represents the molecular Achilles heel in a large subset of difficult-to-treat human cancers.
Eisbach Bio’s innovative approach focuses on exploiting the unique genetic vulnerabilities present in solid tumors with deficiencies in certain DNA repair pathways. Eisbach’s proprietary ALLOS platform systematically recapitulates the tight controls that strictly regulate the activity of several key cancer-driving molecular machines. This facilitated the development of a selective drug that exploits and disrupts a specific and unique mechanism that regulates the activation of the molecular machine ALC1 during DNA repair. This disrupts genome reorganization during DNA repair, halting tumor growth and enabling a new therapeutic approach.
The CPRIT grant will help support the work of Eisbach Bio during the Dose Expansion monotherapy Module 1 of its Phase I/II cancer trial, which is led by Dr. Timothy Yap of The University of Texas MD Anderson Cancer Center in Houston, Texas. EIS-12656 addresses the unmet medical needs of patients with homologous recombination deficient (HRD) cancers who have experienced failure with standard of care therapies. This includes malignant solid tumors, with or without brain metastases, particularly breast, ovarian, pancreatic and prostate cancers, corresponding to ~40,000 patients per year in the US alone.
“We are incredibly honored to receive this support from CPRIT, which underscores the potential of our ALC1 inhibitor EIS-12656 to transform cancer treatment,” said Dr. Adrian Schomburg, Chief Executive Officer at Eisbach Bio GmbH. “This funding validates our unique allosteric approach, which has led to a drug candidate with an exceptional safety profile. The CPRIT award also underlines our commitment to Texas and the robust established relationships that we have developed, including through the Cancer Focus Fund, a unique investment fund established to provide funding and clinical expertise to advance promising cancer therapies. We look forward to accelerating our mission to develop transformative precision medicines, offering new hope to patients with limited treatment options.”
CPRIT’s Product Development Research Program funds projects at Texas-based companies developing novel products or services intended to benefit cancer patients. Eisbach Bio was the only international company that received an award among 90 applicants. Eisbach Bio will increase its activities and footprint in Texas and continue contributing to the state’s exceptional life sciences and biomedicine ecosystems.
For more information about Eisbach Bio and their innovative approach to cancer therapy, please visit www.eisbach.bio.
About Eisbach Bio GmbH
Founded in 2019, Eisbach Bio GmbH is a privately-held company in one of Europe’s largest biotech hubs near Munich, Germany, specializing in the development of precision oncology therapies. By targeting molecular machines that remodel the genome and identifying the unique molecular mechanisms that activate these machines in a controlled manner, Eisbach creates small molecules that target the identified “molecular vulnerability”. By developing allosteric drugs that disrupt these vital molecular controls, Eisbach seeks to develop new and safer approaches to cancer therapy.
About CPRIT
The Cancer Prevention and Research Institute of Texas (CPRIT) was established in 2007 to fund groundbreaking cancer research, drug discovery and prevention programs in Texas. With a $6 billion, 20-year initiative, CPRIT is the largest state cancer research investment in the history of the United States and the second-largest cancer research and prevention program in the world.
Contacts
Eisbach Bio GmbH
Corporate:
Adrian Schomburg, CEO
Media:
Jonathan Iorio
+49 89 2153 79013
MARTINSRIED, Germany, September 16, 2024 – Eisbach Bio GmbH (“Eisbach” or the “Company”), a privately-held clinical-stage biotechnology company pioneering cancer medicines leveraging synthetic lethality, today announced that the first patient has been dosed in Module 1 of the ongoing Phase 1/2 MATCH clinical trial (NCT06525298) investigating the small molecule ALC1 inhibitor EIS-12656 in solid tumors. In this trial, Eisbach seeks to assess the safety, pharmacokinetics, pharmacodynamics and preliminary clinical activity of the allosteric ALC1 inhibitor in the monotherapy setting. The trial, which is being conducted at The University of Texas MD Anderson Cancer Center (MD Anderson), is co-funded with an investment from the Cancer Focus Fund, a unique investment fund established in collaboration with MD Anderson to provide funding and clinical expertise to advance promising clinical therapies
EIS-12656 is a first-in-class, selective, potent, oral and brain-penetrant small molecule inhibitor of the chromatin helicase ALC1 (CHD1L), a key molecular machine involved in DNA damage and genome repair mechanisms. EIS-12656 targets ALC1 through allosteric mechanisms, suppressing the cancer-relevant genome reorganization induced by DNA damage. Eisbach’s preclinical in vivo data with EIS-12656 showed rapid tumor growth inhibition, high bioavailability and excellent tolerability.
“This milestone marks Eisbach’s entry into the cancer clinic with a transformative target and unique allosteric approach. ALC1 is a superior, orthogonal target in tumors with impaired DNA damage and repair. Its inhibitor EIS-12656 is the result of our ability to disrupt the function of the powerful machines that reorganize our genome in a very targeted manner.” said Adrian Schomburg, Ph.D., Founder and CEO of Eisbach. “This clinical study will assess the impact of EIS-12656’s ability to hit both genetic and molecular vulnerabilities in our cancer indications, potentially enabling its advancement as a drug that is both efficacious and well-tolerated.”
About the Phase 1/2 Clinical Trial
The open label study of EIS-12656 will evaluate its safety, tolerability and efficacy in patients with genetically-defined advanced solid tumors. Led by Principal Investigator Timothy A. Yap, M.B.B.S., Ph.D., Vice President, Head of Clinical Development in the Therapeutics Discovery Division and Professor of Investigational Cancer Therapeutics at MD Anderson, the trial includes dose escalation of EIS-12656 monotherapy, followed by dose expansion modules and evaluation in gynecological, pancreatic and prostate cancer patients progressing under PARP inhibitor treatment. Eisbach selected CTI Clinical Trial & Consulting, a global full-service Contract Research Organization, as a strong partner providing regulatory and clinical trial management service for this trial.
About Eisbach
Eisbach is at the forefront of precision oncology, developing allosteric drugs that selectively disrupt molecular machines vital for tumor genome reorganization. Combining genetic vulnerabilities with its proprietary ALLOS platform, which hits the molecular vulnerability of its cancer targets, Eisbach pioneers first-in-class therapies with fewer side effects. For more information, visit https://www.eisbach.bio and follow us on LinkedIn.
Contacts
Eisbach Bio GmbH
Corporate:
Adrian Schomburg, CEO
Media:
Jonathan Iorio
+49 89 2153 79013
Munich, 18.07.2024: Eisbach Bio GmbH is set to train the next generation of scientists in the metabolic regulation of genome function through the innovative project NUCLEAR. Coordinated by the Josep Carreras Leukaemia Research Institute near Barcelona, Spain, this network will guide 17 doctoral candidates to become world-class experts and provide new insights at the interface of metabolism and genome regulation, a topic highly relevant to stem cell biology, obesity and cancer. This project is a Marie Skłodowska Curie Action Doctoral Network funded by the European Commission under the Horizon Europe framework program.
Metabolism is not only a consequence of cell identity, but plays an active role in cell-fate decisions and human disease. By altering chromatin structure, cellular metabolism influences gene expression, impacting both stem and cancer cells. Eisbach will investigate new paradigms of metabolism–chromatin interaction and translate this knowledge into novel targets for cancer treatment.
Given the interdisciplinary nature of this emerging field, NUCLEAR will unite European leaders in metabolomics, functional genomics, chromatin regulation, stem cell biology and cancer. Innovators in precision biology, nutrition, ‘omics and drug R&D, including Eisbach Bio GmbH, complement the network’s broad research, training, education and translation.
NUCLEAR’s core aim is to develop a generation of creative, entrepreneurial and innovative researchers. Our science graduates will translate their knowledge into novel therapies and generate great value for society, ensuring the project’s long-term impact on biomedicine.
As core partner, Eisbach Bio GmbH looks forward to this pioneering research and training PhD candidates at the following leading institutions will drive our research innovation:
- Josep Carreras Leukaemia Research Institute (Spain)
- Universitetet i Bergen (Norway)
- University of Milan (Italy)
- Leibniz-Institut für Analytische Wissenschaften (Germany)
- Max Delbrück Zentrum (Germany)
- Universitetet i Tromsø – Norges Arktiske Universitet (Norway)
- University of Copenhagen (Denmark)
- Universitair Medisch Centrum Utrecht (Netherlands)
- Stichting Radboud University (Netherlands)
- Centre for Genomic Regulation (Spain)
- Karolinska Institutet (Sweden)
- University of Cyprus (Cyprus)
- King Abdullah University of Science and Technology (Saudi Arabia)
- The Babraham Institute (United Kingdom)
- And the industrial partners Eisbach Bio GmbH and Precision for Health (Spain)
Further support for the PhD training program comes from Thermo Fisher Scientific (Bremen) GmbH, Stichting SciLink (SciLink), Asociación Española Contra el Cáncer (AECC), Ludwig-Maximilians-Universität München (LMU), Universitat Autònoma de Barcelona (UAB), Universität Duisburg-Essen (UDE), University of Cambridge (CU), Universidad Autónoma de Madrid (UAM), Charité Universitätsmedizin Berlin (CUB), Universitat Pompeu Fabra (UPF), Instituto Europeo di Oncologia SRL (EIO), and Universiteit Utrecht (UU).
This project has received funding from the European Union’s Horizon Europe research and innovation program under the Marie Skłodowska-Curie Grant Agreement No. 101166838.
Eisbach Bio GmbH is excited to be part of this cutting-edge initiative and looks forward to advancing the field of metabolic regulation of genome function.
About Eisbach Bio GmbH
Eisbach Bio GmbH is a LMU spin off established in January 2019 on the Großhadern-Martinsried campus. Eisbach exploits the innovative therapeutic concept of synthetic lethality in tumor cells and develops small molecule inhibitors for the personalized therapy of cancer in genetically defined patient groups, including for indications with no therapeutic options. Cancer genomics has revealed tumor-specific genes that cancer cells critically depend on for survival. By targeting these molecular vulnerabilities, Eisbach’s inhibitors hit the Achilles heel of tumors, effectively eliminating cancer cells with minimal side effects, while healthy cells remain largely unharmed. Eisbach has developed a proprietary screening and development platform that specifically identifies allosteric inhibitors of these tumor-essential molecular machines, generating efficacious drugs with limited toxicity.
More information:
Eisbach Bio GmbH:
Email: mediarelations@eisbach.bio
The NUCLEAR Project:
MARTINSRIED, Germany, May 24, 2024 – Eisbach Bio GmbH (“Eisbach” or the “Company”), a privately-held clinical-stage biotechnology company pioneering cancer medicines leveraging synthetic lethality, has announced completion and Phase I topline results of EIS-10700. The safety, tolerability and pharmacokinetics of EIS-10700 were investigated in a first-in-human, open label, single center, single dose escalation Phase I study in Germany.
Due to the excellent safety profile obtained in GLP toxicology studies (i.e. MTD in dogs >500 mg/kg), the first cohort of trial participants were given a starting daily dose of 500 mg. The Phase I study enrolled a total of 33 patients in five groups, using escalating dose levels of EIS-10700 in fasted and fed conditions. Subjects received up to the maximum dose of 3.000 mg without a single report of dose limiting toxicity associated with the investigational agent, confirming prior preclinical findings. EIS-10700 demonstrated dose dependent plasma exposure.
“We are excited to complete our first clinical study, which demonstrated the excellent tolerability and PK of EIS-10700.” said Adrian Schomburg, CEO of Eisbach. “Based on the achieved plasma levels, we are excited to now proceed with investigating the anti-tumor efficacy of this first-in-class helicase inhibitor.”
“These results represent another milestone for our proprietary AI-supported ALLOS drug discovery engine. EIS-10700 showed that it is possible to develop safe first-in-class drug candidates targeting helicases.” said Prof. Andreas Ladurner, Founder and CSO of Eisbach. “By integrating structural biology, AI and chemistry, we can target the molecular transitions in machines that are required to reorganize nucleic acids, allowing us to power a differentiated pipeline of safe drugs on novel targets.”
About the EIS-10700 Phase 1 Clinical Trial
First-in-human, open label, single center, single and multiple dose escalation Phase I study in heathy subjects of EIS-10700 conducted in Germany. EIS-10700 is a novel small molecule helicase inhibitor. EIS-10700 is the first clinical program derived from Eisbach’s ALLOS drug discovery engine.
About Eisbach
Eisbach is at the forefront of precision oncology, developing allosteric drugs that selectively disrupt molecular machines vital for tumor genome reorganization. By combining genetic vulnerabilities with its proprietary ALLOS platform, which hits the molecular vulnerability of its cancer targets, Eisbach pioneers first-in-class therapies with fewer side effects. For more information, visit https://www.eisbach.bio/ and follow us on LinkedIn.
Contacts
Eisbach Bio GmbH
Corporate:
Adrian Schomburg, CEO
info@eisbach.bio
Media:
Jonathan Iorio
+49 89 2153 79013
mediarelations@eisbach.bio
MARTINSRIED, Germany, May 6, 2024 – Eisbach Bio GmbH (“Eisbach” or the “Company”), a privately-held clinical-stage biotechnology company pioneering cancer medicines leveraging synthetic lethality, has announced United States Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application for EIS-12656, a small molecule inhibiting the chromatin helicase ALC1 (CHD1L). EIS-12656 targets ALC1 through allosteric mechanisms, suppressing the cancer-relevant genome reorganization induced by DNA damage. This leads to ALC1 chromatin trapping and cancer cell killing.
EIS-12656 impacts tumors deficient in DNA repair pathways. It demonstrated substantial tumor growth inhibition in preclinical models, including in combination with standard-of-care therapies. Its allosteric mechanism of action should afford selectivity compared to related synthetic lethal targets, contributing to the exceptional safety observed in all relevant preclinical models.
“EIS-12656 selectively targets tumors with no apparent effects on normal tissues.” said Adrian Schomburg, Ph.D., Founder and CEO of Eisbach. “Our clinical study will also explore combination therapies that were hindered by combinatorial toxicity in the past.”
The discovery of EIS-12656 builds on the pioneering research of Eisbach founder Prof. Andreas Ladurner, whose team discovered that PARP effects in cancer cells are reliant on chromatin remodeling by ALC1. Eisbach built upon this knowledge and designed a first-in-class, once-daily small molecule therapy, directly targeting cancer genome reorganization induced by DNA damage at its source – the PARP-activated helicase ALC1.
About the Phase 1/2 Clinical Trial
The open label study of EIS-12656 will evaluate its safety, tolerability and efficacy in patients with genetically-defined advanced solid tumors. Led by Principal Investigator Timothy A. Yap, M.B.B.S., Ph.D., Professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, the trial includes dose escalation of EIS-12656 monotherapy, followed by dose expansion modules and evaluation in patients progressing under PARP inhibitor treatment.
About Eisbach
Eisbach is at the forefront of precision oncology, developing allosteric drugs that selectively disrupt molecular machines vital for tumor genome reorganization. Combining genetic vulnerabilities with its proprietary ALLOS platform, which hits the molecular vulnerability of its cancer targets, Eisbach pioneers first-in-class therapies with fewer side effects. For more information, visit https://www.eisbach.bio/ and follow us on LinkedIn.
Contacts
Eisbach Bio GmbH
Corporate:
Adrian Schomburg, CEO
info@eisbach.bio
Media:
Jonathan Iorio
+49 89 2153 79013
mediarelations@eisbach.bio
MARTINSRIED, Germany and HOUSTON, Texas, March 21, 2024 – Eisbach Bio GmbH (Eisbach), a clinical-stage biotechnology company pioneering a new class of cancer medicines leveraging synthetic lethality to target specific proteins that are essential for the survival of cancer cells, and Cancer Focus Fund, LP, a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) to provide funding and clinical expertise to advance promising cancer therapies, today announced that Cancer Focus Fund is investing $4.5 million to support a Phase 1/2 clinical trial of Eisbach’s lead candidate, EIS-12656, which will be conducted at MD Anderson.
EIS-12656 is a small molecule designed to treat tumors that are refractory or resistant to PARP inhibitors. PARP enzymes are involved in critical DNA repair processes. By hindering DNA repair, PARP inhibitors cause tumor cell death, and they have been effective therapies for many ovarian, breast, prostate, and pancreatic cancers. However, their use has been limited by serious toxicities and the development of resistance. EIS-12656 inhibits the chromatin remodeling enzyme ALC1, which is critical to the DNA repair process associated with PARP activation. EIS-12656 was developed by Eisbach to disrupt DNA-damage-dependent PARP activation at an early stage of the repair process. In preclinical studies EIS-12656 overcame PARP inhibitor resistance and demonstrated a benign toxicity profile and blood-brain-barrier penetrance, as well as synergy with PARP inhibitors and other standard-of-care therapies.
“Overcoming the widespread resistance and debilitating side-effects of PARP inhibitors required us to re-think how we tackle the genetic vulnerabilities prevalent in these tumors,” said Dr. Adrian Schomburg, Founder and CEO of Eisbach. “EIS-12656 is a first-in-class small molecule that targets and shuts down the molecular process that reorganizes the tumor genome upon DNA damage and PARP activation – a process that is essential to the survival of cancer cells. Based on its exceptional safety profile and promising activity in preclinical studies, we believe that EIS-12656 has the potential to benefit the many patients with tumors refractory to PARP inhibitors –patients who have few treatment options available today.”
Dr. Andreas Ladurner, Founder and CSO of Eisbach, and Professor and Chair of Physiological Chemistry at Ludwig-Maximilians-University of Munich, commented, “Most cancers contain genome reorganization mechanisms that play critical and very specific roles in tumor biology. By identifying how each of these vital mechanisms is selectively regulated, we can exploit unique molecular vulnerabilities. This approach holds great promise for the discovery of new cancer drugs that are both selective and safe.”
“Eisbach’s distinctive and scientifically sophisticated approach to addressing common difficult-to-treat cancers aligns perfectly with our goals at Cancer Focus Fund,” said Ross Barrett, a founder and Managing Partner of Cancer Focus Fund. “We aim to help innovative young companies like Eisbach to rapidly advance unusually promising new cancer drugs into clinical trials with the help of the expert researchers and clinicians at MD Anderson. EIS-12656 has demonstrated the potential to treat many relapsed and refractory tumors more effectively and with fewer side effects than current therapies, and we look forward to following the progress of this exciting first-in-class compound as it proceeds in clinical development. We also are delighted to expand our geographic reach with this first investment in a biotech company based in Germany, with its rich history of biomedical innovation.”
Timothy A. Yap, M.B.B.S., Ph.D., Professor of Investigational Cancer Therapeutics and Vice President and Head of Clinical Development in the Therapeutics Discovery division at MD Anderson, will serve as Principal Investigator of the trial.
About the EIS-12656 Phase 1/2 Clinical Trial
The Phase 1/2 open label study will assess the safety, tolerability, and efficacy of EIS-12656 as solo therapy in patients with various solid tumors. The study will involve dose escalation of EIS-12656 monotherapy to establish safety and determine the maximum tolerated dose and recommended Phase 2 dose. In the following stage, dose expansion modules will be conducted with EIS-12656 monotherapy. Additional modules will involve patients progressing under PARP inhibitor treatment.
About EIS-12656, a small molecule inhibitor of ALC1 (CHD1L)
EIS-12656, the lead oncology program at Eisbach, is a first-in-class allosteric small molecule inhibitor targeting the PARP-activated chromatin remodeling helicase ALC1 (also known as CHD1L). The cancer-relevant genome reorganization induced by PARP activation is critically dependent on ALC1 activity. Genetic data have revealed that disruption of this ALC1 activity greatly potentiates PARP inhibitors and produces synthetic lethality in BRCA gene mutations. EIS-12656 was developed by exploiting Eisbach’s ALLOS drug discovery platform that recapitulates the selective, unique, and physiological activation mechanism of its target enzymes in the laboratory. Preclinical data showed that EIS-12656 disrupted cancer cell growth by interfering with the DNA damage and repair (DDR) mechanisms of cancer cells while exhibiting a markedly superior toxicity profile in comparison with currently available therapies targeting DDR pathways. With its first-in-kind, allosteric inhibitory mechanism and superior toxicity profile, EIS-12656 may enable novel monotherapy applications and powerful combination therapies.
About Eisbach
Eisbach is a pioneering, clinical-stage biotech company focused on precision oncology, aiming to disrupt tumor growth by targeting genetic vulnerabilities. The company develops allosteric drugs that selectively disrupt molecular mechanisms, also known as molecular machines, which are vital for tumor genome reorganization. Eisbach combines the genetic vulnerabilities present in defined tumors (synthetic lethality) with its proprietary drug discovery platform, ALLOS, which targets the unique molecular vulnerability of its drug targets, to create first-in-class therapies with fewer side effects. The company’s pipeline includes several small molecule candidates targeting chromatin reorganization that enable potent combination therapies and suppress resistance mechanisms in cancer treatment. For more information, visit www.eisbach.bio and follow us on LinkedIn.
About Cancer Focus Fund
The Cancer Focus Fund LP is a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center (MD Anserson). The fund provides investment support to advance promising cancer therapies that are close to being tested in humans or are in early clinical development, as well as the clinical trial expertise and infrastructure of MD Anderson and strategic partners Ochsner Health System Precision Cancer Therapies Program New Orleans and the LSU Feist Weiller Cancer Center Shreveport. The Fund’s objective is to leverage this unique combination to provide investors with superior risk-adjusted returns. In collaboration with partner MD Anderson, the Cancer Focus Fund provides both capital and translational research expertise with the goal of accelerating the development of novel cancer therapies that result in better outcomes for patients while generating returns for investors.
Disclosures
The University of Texas MD Anderson Cancer Center’s relationship with Cancer Focus Fund, and all research conducted at MD Anderson related to Cancer Focus Fund, has been identified as an institutional financial conflict of interest by MD Anderson’s Institutional Conflict of Interest Committee and therefore is managed under an Institutional Conflict of Interest Management and Monitoring Plan.
Forward-Looking Statement
This press release contains forward-looking statements that involve risks and uncertainties, including those related to the clinical development of EIS-12656 and other potential therapies. Actual results may differ materially from those projected in these forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the progress of clinical trials, regulatory approvals, market demand for new therapies, and competitive dynamics in the biotechnology sector.
Contacts
Eisbach Bio GmbH
Corporate:
Adrian Schomburg, CEO
Media:
Jonathan Iorio
+49 89 2153 79013
Cancer Focus Fund
Corporate:
Ross Barrett
Managing Partner
Media:
Barbara Lindheim
BLL Partners for Cancer Focus Fund
+1 917 355-9234
Munich, 26.04.2023:
Eisbach Bio GmbH, a biotechnology company targeting the molecular machines that drive human disease, today announced the start of a Phase 1, first-in-human clinical trial for EIS-10700, a small molecule that targets the RNA helicase of SARS-CoV-2. Eisbach Bio is developing a COVID-19 antiviral as part of the EisCor2 project supported by the German Federal Ministry of Research (BMBF).
The trial is designed to evaluate the safety, tolerability, and pharmacokinetics of their proprietary helicase inhibitor in healthy volunteers. Emerging from Eisbach’s drug discovery platform, EIS-10700 is a novel, SARS-CoV-2-directed small molecule helicase inhibitor that has been developed to suppress viral replication through a mechanism that is conserved across all known COVID-19 variants, thus resistant to potential mutations.
The drug candidate has shown promising results in preclinical studies. The company is now moving forward with clinical trials to further evaluate its safety and tolerability.
“We are excited to announce the initiation of Phase 1 clinical trials for EIS-10700, our first-in-class SARS-CoV-2 helicase inhibitor,” said Dr. Adrian Schomburg, CEO of Eisbach Bio GmbH. “This is an important milestone in the development of our drug, and we look forward to advancing it through clinical trials. We aim to deliver a sustainable medicine to globally reduce COVID-19 hospitalizations and deaths.” The Phase 1 trial will be conducted in collaboration with Nusivan GmbH in Germany and receives support from the German Ministry for Education and Research (BMBF) in the context of the funded EisCor2 project. Eisbach Bio GmbH expects to complete the trial in the coming months and to advance the drug into later-stage clinical trials to test its antiviral efficacy.
About Eisbach Bio GmbH
Eisbach develops novel drugs targeting helicase enzymes, including molecular machines that are essential to tumors with defined genetic vulnerabilities in the context of DNA damage and repair (DDR). Its proprietary helicase platform and discovery engine ALLOS creates targeted therapies that exploit disease-relevant vulnerabilities. By shutting off the machines’ engines using allosteric inhibitors, Eisbach’s impactful medicines prevent the reorganization and evolution of cancer genomes. Founded in 2019, Eisbach is privately held and backed by international investors. For more information, please visit www.eisbach.bio.
More information:
Eisbach Bio GmbH:
Email: info@eisbach.bio
A nucleic acid chemistry cluster to shape Germany’s R&D future – Eisbach member of the winning C-NATM cluster
Munich, 08.08.2022: The cluster C-NATM has emerged as one of the 7 winners in the Clusters4Future competition funded by the German Federal Ministry of Education and Research (BMBF). Eisbach Bio GmbH will contribute its proprietary R&D expertise to the network and develop novel nucleic acid-based therapies for oncology.
The C-NATM network led by Prof. Dr. Thomas Carell and Prof. Dr. Stefan Engelhardt aims to develop new drugs and next generation vaccines based on nucleic acids to cure currently untreatable diseases. Recent discoveries in the field of mRNA vaccines, but also in the field of chemical biology, epigenetics and nucleic acid therapies, now give hope that nucleic acids and related molecules have therapeutic potential as new “weapons” in the anti-viral, anti-cancer and immune modulation field. The cluster includes leading academic and industrial partners. Together, they will develop highly innovative therapeutics in the field of nucleic acid chemistry. Alongside with Roche, Eisbach is committed to support the network over a period of at least 3 years.
Eisbach Bio GmbH’s expertise in drug discovery and development to address nucleic acid-modifying molecular machines for antitumor therapy makes the company an ideal industrial partner for the ambitious project at the interface of chemistry and medicine.
About Eisbach Bio GmbH
Eisbach Bio GmbH is a LMU spin off established in January 2019 on the Großhadern-Martinsried campus. Eisbach exploits the innovative therapeutic concept of synthetic lethality in tumor cells and develops small molecule inhibitors for the personalized therapy of cancer in genetically defined patient groups, including for indications with no therapeutic options. Cancer genomics has revealed tumor-specific genes that cancer cells critically depend on for survival. By targeting these molecular vulnerabilities, Eisbach’s inhibitors hit the Achilles heel of tumors, effectively eliminating cancer cells with minimal side effects, while healthy cells remain largely unharmed. Eisbach has developed a proprietary screening and development platform that specifically identifies allosteric inhibitors of these tumor-essential molecular machines, generating efficacious drugs with limited toxicity.
About the BMBF’s Future Clusters Initiative:
The German federal Clusters4Future initiative seeks to bring innovations to market. To ensure that Germany remains in the top group of innovation leaders, the BMBF launched an ambitious program to establish several regional R&D clusters that catalyze the existing research cooperation between leading academic institutions and industry.
The fourteen future clusters in total are Germany’s innovation networks of the future. Their aim is to find suitable solutions for the major challenges of our time. The topics are as diverse as the winners’ concepts: neuromorphic hardware for autonomous systems, personalized cell and gene therapy processes, sustainable marine research, quantum technology, new approaches to drug discovery and development, as well as hydrogen fuel technologies. To this end, universities, research institutions, companies, social and other relevant players in the regions have joined forces, sharing exclusive knowledge with each other and pooling their expertise into joint R&D activities.
More information:
Eisbach Bio GmbH:
Email: info@eisbach.bio
Cluster4Future:
https://www.clusters4future.de
C-NATM:
Eisbach Bio and MD Anderson announce strategic collaboration to develop medicines targeting epigenetic machinery in oncology
MUNICH and HOUSTON ― Eisbach Bio GmbH and The University of Texas MD Anderson Cancer Centertoday announced a strategic research collaboration to jointly discover and develop precision oncology drugs that target synthetic lethal engines key to tumor genome evolution.
The agreement aligns the drug discovery and development expertise of MD Anderson’s Therapeutics Discovery division with the innovative discovery platform and allosteric assay technology of Eisbach to generate medicines that selectively disrupt genome replication and DNA repair in cancers harboring defined genetic alterations.
“Modern genomics has revealed synthetic lethal targets in certain cancers with tumor suppressor gene mutations, and Eisbach has developed tools to pinpoint precisely where these targets are vulnerable at the molecular level,” said Adrian Schomburg, Ph.D., Chief Executive Officer of Eisbach. “We are excited to collaborate with MD Anderson to develop innovative targeted therapies that exploit these unique vulnerabilities.”
Synthetic lethality is a phenomenon in which cancer cells with mutations in certain pathways are hypersensitive to drugs targeting related pathways. Notably, defects in certain DNA damage repair pathways – common to many cancer types – render cancer cells dependent on processes that reorganize the cancer genome.
“Cancers harboring mutations in tumor suppressor genes have been notoriously difficult to treat in the past,” said Timothy A. Yap, M.B.B.S., Ph.D., Associate Professor of Investigational Cancer Therapeutics and Medical Director of the Institute for Applied Cancer Science (IACS) at MD Anderson. “However, growing clinical evidence with PARP inhibitors demonstrates that targeting synthetic lethality is a promising strategy in certain cancer types, and we look forward to continued progress in this space.”
Eisbach and MD Anderson will leverage their complementary expertise to jointly identify targets and develop small-molecule therapies that can shut off specific epigenetic processes, thereby disrupting genome control selectively in tumor cells while sparing normal tissues. With its proprietary assay platform, Eisbach is uniquely capable of identifying and targeting molecular vulnerabilities in this machinery through allosteric mechanisms.
“Our platform identifies the unique activation mechanisms of molecular machines essential for cancer cell growth,” said Andreas Ladurner, Ph.D., Chief Scientific Officer at Eisbach. “With this insight, we are able to develop targeted drugs that selectively interfere with the ignition of the engines that tumor cells have come to rely upon. These drugs are safe and selective by design.”
Eisbach will collaborate with the team at IACS, a drug discovery engine focused on developing novel small-molecule therapeutics. IACS is a core component of MD Anderson’s Therapeutics Discovery division, an integrated team of researchers, physicians and drug development experts working to advance impactful new therapies.
“Our Therapeutics Discovery team is committed to developing the next generation of cancer treatments that address significant unmet needs in oncology,” said Philip Jones, Ph.D., Vice President of Therapeutics Discovery and Head of IACS at MD Anderson. “By focusing on epigenetic machinery in our collaboration with Eisbach, we are hoping to advance additional much-needed therapeutic options that can improve patients’ lives.”
Under the terms of the agreement, Eisbach and MD Anderson will jointly determine the appropriate pathway for future development and possible commercialization on any therapies that show promise in laboratory studies.
About Eisbach Bio GmbH
Eisbach Bio develops novel drugs that disrupt molecular machines essential to tumors with defined genetic vulnerabilities in the context of DNA damage and repair (DDR) pathways. Its proprietary platform creates targeted therapies that exploit disease-relevant vulnerabilities. By shutting off the machine’s engine using allosteric inhibitors, their impactful medicines prevent thereorganization and evolution of cancer genomes. Founded in 2019, Eisbach is privately held and backed by international investors.
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world’s most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 51 comprehensive cancer centers designated by the National CancerInstitute (NCI). MD Anderson is No. 1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings. It has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).
More information:
Eisbach Bio GmbH:
Email: info@eisbach.bio
The University of Texas M. D. Anderson Cancer Center
Email: publicrelations@mdanderson.org
Eisbach Bio receives €6.7M grant from the Bavarian Government for the development of targeted SARS-CoV-2 antivirals
MUNICH, Germany, October 29, 2021 – Eisbach Bio, a biotechnology company targeting the molecular machines that drive human disease, announces financial support from the Bavarian Ministry of Economic Affairs, Regional Development and Energy (StMWi) for the preclinical and clinical development of a proprietary SARS-CoV-2 helicase inhibitor and its backups. The funding of EUR 6.7 million will support the development of the Company’s COVID-19 therapeutics and maintain the competitiveness of the biotech scene in Bavaria as part of the BayTherapie 2020 program.
Eisbach aims to bring a safe, sustainable and targeted antiviral drug with specific activity against the SARS-CoV-2 virus into the clinic to lower disease progression and help end the pandemic globally. Using its molecular machine expertise, the Company developed EIS4363, a small molecule inhibitor of the SARS-CoV-2 helicase enzyme Nsp13, which is critical for viral replication and is the most conserved non-structural protein within the extended coronavirus family. The goal of this project is to further develop the chemical structure of the preclinical candidate EIS4363 and to further increase the efficacy in animal models. Additional research will be directed toward developing a highly effective, oral combination therapy with drugs targeting the RNA-dependent RNA polymerase (RdRP), such as molnupiravir.
Eisbach’s CEO, Dr. Adrian Schomburg, commented: “Our team is grateful to receive state support for the development of our drug candidates. The biotech scene in Bavaria and beyond will benefit from this project. Our research progress illustrates how Bavarian companies joined the fight against COVID-19, taking a leading role in driving innovation and identifying therapeutic solutions.”
Prof. Andreas Ladurner, Eisbach’s CSO, added: “We are determined to deliver a sustainable drug with a good safety profile. The funded BayTherapie2020 program will allow us to allocate more resources to the research and development of EIS4363, greatly increasing our chances of developing a much-needed novel antiviral for the global community.”
The financial support adds to the Company’s government-funded grants for the development of its novel targeted antivirals. Eisbach is rapidly progressing its IND-enabling work and expects to initiate Phase I clinical trials for its nominated COVID-19 asset in Q2, 2022.
About Eisbach Bio GmbH:
Eisbach develops novel drugs that disrupt molecular machines essential to tumors with defined genetic vulnerabilities in the context of DNA damage and repair (DDR). Its proprietary allosteric platform creates targeted therapies that exploit disease-relevant vulnerabilities. By shutting off the machine’s engine using allosteric inhibitors, Eisbach’s medicines are designed to prevent the reorganization and evolution of cancer genomes. In early 2020, Eisbach joined the global effort to fight the COVID-19 pandemic by exploiting its allosteric platform for the identification of small molecule antivirals targeting related molecular machines and engines in SARS-CoV-2. Founded in 2019, Eisbach is privately held and backed by international investors. For more information, please visit www.eisbach.bio.
More information:
Eisbach Bio GmbH
Email: info@eisbach.bio
Press Release
Collaboration Eisbach Bio GmbH & Technische Universität Kaiserslautern
MUNICH, Germany, September 1, 2021 – Eisbach Bio GmbH and the team of Prof. Dr.-Ing. Naim Bajcinca from the Technische Universität Kaiserlautern (TUK) announce a collaboration where they will use deep learning to track and trace arising mutations in the genome of SARS-CoV-2 and develop sustainable small molecule inhibitors that will target the virus for the long-term.
The project titled AI-based Mutation Prediction and Relevant Protein Inhibitor Development in SARS-CoV-2 (AIMPID) is focused on predicting mutations in the SARS-CoV-2 genome and developing small inhibitor molecules which target the virulent protein products of predicted mutations to block their activities. Being an RNA virus, SARS-CoV-2 is prone to mutations in its genome. These mutations will likely render current vaccines and drugs less effective over time. The tracing of mutation patterns in the viral genome will allow for the identification of the least mutable regions. This knowledge will help the collaborating teams to design more enduring, sustainable inhibitor molecules, which will help controlling the global spread of pandemic. The main tasks of the project include the prediction of the mutation rate, of the specific mutated residues among all viral proteins and the development of small inhibitor molecules against one or more specific target proteins translated from the virus’ mutated RNA sequences. One objective of the collaboration is to generate a small molecule inhibitor of a critical SARS-CoV-2 protein that has the potential to inhibit current and future variants of the SARS-CoV-2 virus.
The project is partially financed by the ZIM Programme of the Federal Ministry for Economic Affairs and Energy (www.zim.de). It is a collaboration between Eisbach’s R&D department and the Chair of Mechatronics in Mechanical and Automotive Engineering of the TUK.
The development of antiviral drugs based on deep learning shall complete Eisbach’s other COVID-19 assets and will run in parallel to already developed small molecule inhibitors.
More information:
Eisbach Bio
Email: info@eisbach.bio
Technische Universität Kaiserslautern
Chair of Mechatronics in Mechanical and Automotive Engineering
Email: ahtisham.abbasi@mv.uni-kl.de
Press Release
Eisbach Bio receives EUR 8 million government grant to progress COVID-19 antiviral through Phase I/II clinical development
MUNICH, Germany, July 7, 2021 – Eisbach Bio, a biotechnology company targeting the molecular machines that drive human disease, today announced additional financial support from the German Ministry for Education and Research (BMBF) for the clinical development of its first-in-class SARS-CoV-2 helicase inhibitor. The total funding of EUR 8 million will support the clinical development of the Company’s novel COVID-19 therapeutic following the recent completion of its preclinical development.
Eisbach is using its allosteric inhibitor platform to develop selective drugs for the inhibition of complex molecular machines involved in serious diseases. In cancer, it has identified synthetic-lethal and oncogenic helicases as targets and developed small-molecule inhibitors targeting specific chromatin remodeling enzymes. Using its helicase expertise, the Company also developed an inhibitor of the SARS-CoV-2 helicase Nsp13, an RNA helicase critical for viral replication and the most conserved non-structural protein within the coronavirus family.
Eisbach’s CEO, Dr. Adrian Schomburg, commented: “We are very thankful to receive BMBF support for the clinical validation of our drug candidate, which allows for convenient oral administration. As the tablets can be easily manufactured and shipped, our drug candidate not only offers broad potential to alleviate disease symptoms, but also to globally reduce COVID-19 hospitalizations and deaths.”
Prof. Andreas Ladurner, Eisbach’s CSO, added: “Our drug blocks viral replication through a novel, targeted mechanism that is fully conserved across all known virus variants. We are determined to deliver a sustainable drug with a good safety profile that should allow treatment of anyone testing positive for SARS-CoV-2, especially high-risk patients.”
The antiviral adds to the Company’s original oncology pipeline, consisting of first-in-kind inhibitors for synthetic-le thal cancer targets. Eisbach is rapidly progressing its IND-enabling work and expects to initiate Phase I clinical trials for its COVID-19 asset in Q1, 2022.
###
About Eisbach Bio GmbH
Eisbach develops novel drugs that disrupt molecular machines essential to tumors with defined genetic vulnerabilities in the context of DNA damage and repair (DDR). Its proprietary platform creates targeted therapies that exploit disease-relevant vulnerabilities. By shutting off the machine’s engine using allosteric inhibitors, Eisbach’s medicines are designed to prevent the reorganization and evolution of cancer genomes. Founded in 2019, Eisbach is privately held and backed by international investors. For more information, please visit www.eisbach.bio.
More information:
Eisbach Bio
Email: info@eisbach.bio
Media Inquiries:
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64 /
Tel. +49 30 23 63 27 68
Link to BMBF press release
MUNICH, Germany. April 16th, 2021 – Eisbach Bio, a biotechnology company targeting the molecular machines that drive human disease today announced additional financial support from the German Ministry for Education and Research (BMBF) for the clinical development of its first-in-class SARS-CoV-2 helicase inhibitor. Leveraging Eisbach’s proprietary drug discovery platform, the company has concluded preclinical development of its candidate molecule. Eisbach and 7 additional German companies were awarded BMBF funding to support the clinical development of novel COVID-19 therapeutics, as announced by the Federal Minister for Education and Research, Ms. Anja Karliczek.
Eisbach’s CEO, Dr. Adrian Schomburg, commented: “We are very thankful to receive BMBF support to clinically validate our once-a-day remedy. The tablets are easy to manufacture and distribute, offering the potential to alleviate disease symptoms and globally reduce COVID-19 hospitalizations and deaths.” Prof. Andreas Ladurner, Eisbach’s CSO, added: “Our drug blocks viral replication through a novel, targeted mechanism that is fully conserved across all known virus variants. We are determined to deliver a sustainable medicine with a safety profile that should allow anybody testing positive for SARS-CoV-2 to take this medicine.”
The antiviral adds to the company’s strong oncology pipeline, consisting of first-in-kind inhibitors for two synthetic-lethal cancer targets. Eisbach is rapidly progressing its IND-enabling work and expects to initiate Phase I clinical trials for its COVID-19 asset in Q3 2021.
About Eisbach Bio GmbH:
Eisbach develops novel drugs that disrupt molecular machines essential to tumors with defined genetic vulnerabilities in the context of DNA damage and repair (DDR). Its proprietary platform creates targeted therapies that exploit disease-relevant vulnerabilities. By shutting off the machine’s engine using allosteric inhibitors, their impactful medicines prevent the reorganization and evolution of cancer genomes. Founded in 2019, Eisbach is privately held and backed by international investors. For more information, please visit www.eisbach.bio.
Link to BMBF press release
Collaboration Core Facility Animal Models & Eisbach Bio GmbH
The Core Facility Animal Models (CAM) of the Biomedical Center of the LMU announces a collaboration with drug discovery start-up Eisbach Bio GmbH to test SARS-CoV-2 antivirals.
Eisbach has developed small molecule inhibitors which target disease-relevant and novel mechanisms in SARS-CoV-2 for the treatment of COVID-19 and is now concluding late-stage pre-clinical development together with the CAM. The CAM is conducting animal studies to evaluate the new compounds with respect to their drug metabolism as well as tolerability. The inhibitors which directly shut off viral replication of SARS-CoV-2 could be given so far at high doses with no detectable toxicity nor side effects. Clinical trials are expected to start this summer.
The Core Facility Animal Models (CAM) at the Biomedical Center is a scientific unit of the LMU Munich providing scientists a platform to conduct animal experimentation in accordance with the legal requirements of the European and national (German) law. Core responsibility of the CAM is to care for all on-site animals subject to animal research experimentation. In addition, the CAM team supports scientists in the planning and realization of experiments as well as in providing expert advice and counseling toward legal authorities and government offices.
Eisbach Bio GmbH is a LMU spin off established in January 2019 on the Großhadern-Martinsried campus. The start-up develops novel drugs targeting essential motor proteins through allosteric mechanisms. Their technology allows to develop impactful medicines in oncology, where these machines use their engine’s power to reorganize the human genome, especially in the context of DNA damage and repair. Inhibitors targeting these machines hold great promise in treating cancer. In February 2020, Eisbach joined the worldwide efforts to combat the Coronavirus pandemic and is on-track to develop the first effective, targeted, enduring and sustainable antiviral COVID-19 therapy. The project received funding from the BMBF as part of their call to tackle the pandemic in spring 2020.